Synthetic Cannabinoid Abuse Resulting in ST-Segment Elevation Myocardial Infarction Requiring Percutaneous Coronary Intervention
Authors:
- 1 April 2017
- journal article
- case report
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 52 (4) , 496-498
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pharmacology of Valinate andtert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their AnaloguesACS Chemical Neuroscience, 2016
- Myocardial Ischemia Secondary to Synthetic Cannabinoid (K2) Use in Pediatric PatientsThe Journal of Pediatrics, 2015
- Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135ACS Chemical Neuroscience, 2015
- Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22Journal of Analytical Toxicology, 2014
- K2—Not the Spice of Life; Synthetic Cannabinoids and ST Elevation Myocardial Infarction: A Case ReportJournal of Medical Toxicology, 2014
- Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A reviewJournal of Advanced Research, 2014